Innovative partnerships among researchers, patients, regulators, payors and industry are needed to reinvigorate drug discovery for central nervous system disorders. Here, we summarize plans of the Collegium Internationale Neuro-Psychopharmacologicum (CINP) to achieve this goal.
This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Riordan, H. & Cutler, N. The death of CNS drug development: overstatement or omen? J. Clin. Stud. 3, 12–15 (2011).
Zohar, J. et al. A proposal for an updated neuropsychopharmacological nomenclature. Eur. Neuropsychopharmacol. 24, 1005–1014 (2014).
The authors would like to acknowledge M. Loughlin, Z. Baxter and A. Grigg of Inspired Science who provided medical writing and editorial support.
The author declare no competing financial interests.
About this article
Cite this article
on behalf of the 2013 CINP Summit Group. Securing the future of drug discovery for central nervous system disorders. Nat Rev Drug Discov 13, 871–872 (2014). https://doi.org/10.1038/nrd4489